Skip to main content
Fig. 5 | BMC Biotechnology

Fig. 5

From: Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy

Fig. 5

Flow cytometry binding analysis of the selected scFvs. The stimulated Jurkat T cells were treated with the selected scFvs (SS70, SS 107, SS94, and SS85) and a commercial mouse anti-PD-1 mAb as a positive control (C+) and then stained with FITC conjugated anti-M13 for flow cytometry analysis. Unstimulated Jurkat T cells and anti-c-met scFv as an irrelevant scFv were included as negative controls. Thin line: isotype control, bold line: scFv or commercial anti-PD-1 antibody

Back to article page

BMC Biotechnology

ISSN: 1472-6750

Contact us